论文部分内容阅读
人附睾蛋白4(HE4)在卵巢癌早期诊断、治疗监测及预后评估中具有重要医学价值,临床应用日益广泛。但临床试剂说明书提供的参考范围源于国外人群研究,其正常参考值与中国人群临床所见存在一定差距。使用大规模HE4临床实验数据,按照年龄段或绝经前、后区分参考值,为临床提供适合中国健康人群的HE4参考值意义重大。2012年10月,经中国人民解放军总医院田亚平教授主持的HE4中国人群参考值多中心研究正式启动,由中国人民解放军
Human epididymal protein 4 (HE4) has important medical value in the early diagnosis, treatment monitoring and prognosis evaluation of ovarian cancer, and its clinical application is more and more widely. However, the reference range provided by the clinical reagent manual is derived from the study of the foreign population, and there is a certain gap between its normal reference value and the clinical findings of the Chinese population. Using large-scale clinical trial data of HE4, according to age or pre-menopausal and post-differentiation reference values, it is of great significance to provide HE4 reference value for clinical healthy population in China. In October 2012, HE4 Chinese multicentre multi-center study was officially launched by Prof. Tian Yaping, PLA General Hospital. The Chinese People’s Liberation Army